|Company Name:||Array Biopharma Inc|
|Event Title:||Q4 2013 Earnings Call Transcript|
|Event Time:||09:00 AM ET|
Welcome to the Q4 2013 Array BioPharma Incorporated Earnings Conference Call.
My name is John and I will be your operator for today's call. At this time, all participants are in listen-only mode.
Later, we will conduct a question-and-answer session. Please note that this conference is being recorded.
Now I would like to turn the call over to Tricia Haugeto.
Thank you John. Good morning and welcome once again to Array BioPharma's conference call to discuss our financial results for the fourth quarter and full year of 2013. You can listen to this conference call on Array's website at arraybiopharma.com. Also, we are using slides today to accompany our remarks.
Those slides can be downloaded on the Investor Relations home page of our website. In addition, a replay of the conference call will be available as a webcast from our website.
I'd like to introduce Array's Chief Executive Officer, Ron Squarer and our Chief Financial Officer, Mike Carruthers, who will lead the call today. I would also like to introduce Kevin Koch, our President and Chief Scientific Officer and Mike Needle our Chief Medical Officer, who will be available to answer questions as needed.
But before I handover the call to Ron, I would like to read the following Safe Harbor statement. The matters we are discussing today include projections or other forward-looking statements about the future results research and development goals of Array and its collaborators and future financial performance of Array. These statements are estimates based on management's current expectations and involve risks and uncertainties that could cause them to differ materially from actual results.
We refer you to risk factors discussed in our filings with the SEC including our annual report filed on Form 10-K for the year ended June 30th, 2012 and in other filings Array makes with the SEC. These filings identify important risk factors that could cause actual results to differ materially from those in our projections or forward-looking statements.
Now I'd like to turn it over to Array's CEO, Ron Squarer.
Chief Executive Officer
Thank you Tricia and good morning to everyone. Thank you for joining our fourth quarter and full fiscal year call.
Turning to slide three, I'd like to review the great progress we've made this past fiscal year across our development stage portfolio including our wholly-owned Hem/Onc programs, our MEK-partnered programs and our novel oral CRTh2 antagonist for asthma.